Your browser doesn't support javascript.
Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19.
Berry, Donald A; Ip, Andrew; Lewis, Brett E; Berry, Scott M; Berry, Nicholas S; MrKulic, Mary; Gadalla, Virginia; Sat, Burcu; Wright, Kristen; Serna, Michelle; Unawane, Rashmi; Trpeski, Katerina; Koropsak, Michael; Kaur, Puneet; Sica, Zachary; McConnell, Andrew; Bednarz, Urszula; Marafelias, Michael; Goy, Andre H; Pecora, Andrew L; Sawczuk, Ihor S; Goldberg, Stuart L.
  • Berry DA; Berry Consultants LLC, Austin, Texas, United States of America.
  • Ip A; M.D. Anderson Cancer Center of the University of Texas, Houston, Texas, United States of America.
  • Lewis BE; Division of Outcomes and Value Research, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Berry SM; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Berry NS; Hackensack Meridian Health School of Medicine, Nutley, New Jersey, United States of America.
  • MrKulic M; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Gadalla V; Hackensack Meridian Health School of Medicine, Nutley, New Jersey, United States of America.
  • Sat B; Berry Consultants LLC, Austin, Texas, United States of America.
  • Wright K; Berry Consultants LLC, Austin, Texas, United States of America.
  • Serna M; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Unawane R; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Trpeski K; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Koropsak M; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Kaur P; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Sica Z; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • McConnell A; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Bednarz U; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Marafelias M; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Goy AH; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Pecora AL; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Sawczuk IS; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
  • Goldberg SL; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
PLoS One ; 16(7): e0255228, 2021.
Article in English | MEDLINE | ID: covidwho-1334774
ABSTRACT

OBJECTIVES:

The development of a prognostic mortality risk model for hospitalized COVID-19 patients may facilitate patient treatment planning, comparisons of therapeutic strategies, and public health preparations.

METHODS:

We retrospectively reviewed the electronic health records of patients hospitalized within a 13-hospital New Jersey USA network between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2, with follow-up through May 29, 2020. With death or hospital discharge by day 40 as the primary endpoint, we used univariate followed by stepwise multivariate proportional hazard models to develop a risk score on one-half the data set, validated on the remainder, and converted the risk score into a patient-level predictive probability of 40-day mortality based on the combined dataset.

RESULTS:

The study population consisted of 3123 hospitalized COVID-19 patients; median age 63 years; 60% were men; 42% had >3 coexisting conditions. 713 (23%) patients died within 40 days of hospitalization for COVID-19. From 22 potential candidate factors 6 were found to be independent predictors of mortality and were included in the risk score model age, respiratory rate ≥25/minute upon hospital presentation, oxygenation <94% on hospital presentation, and pre-hospital comorbidities of hypertension, coronary artery disease, or chronic renal disease. The risk score was highly prognostic of mortality in a training set and confirmatory set yielding in the combined dataset a hazard ratio of 1.80 (95% CI, 1.72, 1.87) for one unit increases. Using observed mortality within 20 equally sized bins of risk scores, a predictive model for an individual's 40-day risk of mortality was generated as -14.258 + 13.460*RS + 1.585*(RS-2.524)^2-0.403*(RS-2.524)^3. An online calculator of this 40-day COVID-19 mortality risk score is available at www.HackensackMeridianHealth.org/CovidRS.

CONCLUSIONS:

A risk score using six variables is able to prognosticate mortality within 40-days of hospitalization for COVID-19. TRIAL REGISTRATION Clinicaltrials.gov Identifier NCT04347993.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hospital Mortality / SARS-CoV-2 / COVID-19 / Hospitalization / Models, Biological Type of study: Cohort study / Diagnostic study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0255228

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hospital Mortality / SARS-CoV-2 / COVID-19 / Hospitalization / Models, Biological Type of study: Cohort study / Diagnostic study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0255228